Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI)

Annals of Surgical Oncology

Volumn 16, Issue 7, 2009, Pages 2018-2027

  Testori, Alessandro ^a   De Salvo, Gian Luca ^b   Montesco, Maria Cristina ^c   Trifirò, Giuseppe ^a   Mocellin, Simone ^d   Landi, Giorgio ^e   MacRipò, Giuseppe ^f   Carcoforo, Paolo ^g   Ricotti, Giuseppe ^h   Giudice, Giuseppe ⁱ   Picciotto, Franco ^j   Donner, Davide ^k   Di Filippo, Franco ^l   Soteldo, Javier ^a   Casara, Dario ^b   Schiavon, Mauro ^m   Vecchiato, Antonella ^b   Pasquali, Sandro ^d   Baldini, Federica ^a   Mazzarol, Giovanni ^a   Rossi, Carlo Riccardo ^d   more..

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e BUFALINI HOSPITAL   (Italy)

^f Ospedale San Lazzaro   (Italy)

^g UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^h Ospedale Sestilli   (Italy)

ⁱ UNIVERSITY OF BARI   (Italy)

^j CANDIOLO CANCER INSTITUTE   (Italy)

^k SANTA CHIARA HOSPITAL   (Italy)

^l REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^m UNIVERSITY HOSPITAL OF UDINE   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENDER; HEALTH CENTER; HEALTH STATUS; HISTOPATHOLOGY; HUMAN; ITALY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PREDICTION; PROGNOSIS; PROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FALSE NEGATIVE REACTIONS; FEMALE; HUMANS; ITALY; LYMPH NODES; MALE; MELANOMA; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; YOUNG ADULT;

EID: 67649198517     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-008-0273-8     Document Type: Article

References (46)

1. Morton DL. Lymphatic mapping and sentinel lymphadenectomy for melanoma: past, present, and future. Ann Surg Oncol. 2001;8(9 Suppl):22S-8S.
2. Eggermont AM, Suciu S, Santinami M, et al. EORTC 18991: long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma, final results of a randomized phase III trial [abstract]. J Clin Oncol. 2007;25(18 Suppl):8504.
3. Sondak VK, Taylor JM, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol. 2004;11(3):247-58.
4. Paek SC, Griffith KA, Johnson TM, et al. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer. 2007;109(1):100-8.
5. Kruper LL, Spitz FR, Czerniecki BJ, et al. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma. Cancer. 2006;107(10):2436-45.
6. Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS. Tumorinfiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol. 2007;25(7):869-75.
7. Mocellin S, Ambrosi A, Montesco MC, et al. Support vector machine learning model for the prediction of sentinel node status in patients with cutaneous melanoma. Ann Surg Oncol. 2006;13(8):1113-22.
8. Nowecki ZI, Rutkowski P, Nasierowska-Guttmejer A, Ruka W. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma. Ann Surg Oncol. 2006;13(12):1655- 63.
9. Thompson JF, Stretch JR, Uren RF, Ka VS, Scolyer RA. Sentinel node biopsy for melanoma: Where have we been and where are we going? Ann Surg Oncol. 2004;11(3 Suppl):147S-51S.
10. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355(13):1307-17.
11. Caraco C, Marone U, Celentano E, Botti G, Mozzillo N. Impact of false-negative sentinel lymph node biopsy on survival in patients with cutaneous melanoma. Ann Surg Oncol. 2007;14(9):2662-7.
12. Morton DL, Scheri RP, Balch CM. Can completion lymph node dissection be avoided for a positive sentinel node in melanoma? Ann Surg Oncol. 2007;14(9):2437-9.
13. Cascinelli N, Bombardieri E, Bufalino R, et al. Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. J Clin Oncol. 2006;24(27):4464-71.
14. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19(16):3622-34.
15. Mocellin S, Hoon DS, Pilati P, Rossi CR, Nitti D. Sentinel lymph node molecular ultrastaging in patients with melanoma: a systematic review and meta-analysis of prognosis. J Clin Oncol. 2007;25(12):1588-95.
16. Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005;242 (3):302-13.
17. Agnese DM, Abdessalam SF, Burak WE Jr, Magro CM, Pozderac RV, Walker MJ. Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery. 2003;134(4):542-8.
18. Rossi CR, De Salvo GL, Bonandini E, et al. Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node. Ann Surg Oncol. 2008;15(4):1202-10.
19. http://clinicaltrials.gov/show/NCT00297895.
20. Thomas JM. Time for comprehensive reporting of MSLT-I. Lancet Oncol. 2006;7(1):9-12.
21. Rossi CR, De Salvo GL, Trifiro G, et al. The impact of lymphoscintigraphy technique on the outcome of sentinel node biopsy in 1,313 patients with cutaneous melanoma: an Italian Multicentric Study (SOLISM-IMI). J Nucl Med. 2006;47(2):234-41.
22. Cook MG, Spatz A, Brocker EB, Ruiter DJ. Identification of histological features associated with metastatic potential in thin (\1.0 mm) cutaneous melanoma with metastases A study on behalf of the EORTC Melanoma Group. J Pathol. 2002;197 (2):188-93.
23. Blessing K, McLaren KM, McLean A, Davidson P. Thin malignant melanomas (less than 15 mm) with metastasis: a histological study and survival analysis. Histopathology. 1990; 17(5):389-95.
24. Gromet MA, Epstein WL, Blois MS. The regressing thin malignant melanoma: a distinctive lesion with metastatic potential. Cancer. 1978;42(5):2282-92.
25. Guitart J, Lowe L, Piepkorn M, et al. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol. 2002;138(5):603-8.
26. Ronan SG, Eng AM, Briele HA, Shioura NN, Das Gupta TK. Thin malignant melanomas with regression and metastases. Arch Dermatol. 1987;123(10):1326-30.
27. Slingluff CL Jr, Vollmer RT, Reintgen DS, Seigler HF. Lethal ''thin'' malignant melanoma. Identifying patients at risk. Ann Surg. 1988;208(2):150-61.
28. Shaw HM, McCarthy SW, McCarthy WH, Thompson JF, Milton GW. Thin regressing malignant melanoma: significance of concurrent regional lymph node metastases. Histopathology. 1989;15(3):257-65.
29. Fontaine D, Parkhill W, Greer W, Walsh N. Partial regression of primary cutaneous melanoma: is there an association with subclinical sentinel lymph node metastasis? Am J Dermatopathol. 2003;25(5):371-6.
30. Kaur C, Thomas RJ, Desai N, et al. The correlation of regression in primary melanoma with sentinel lymph node status. J Clin Pathol. 2008;61(3):297-300.
31. Liszkay G, Orosz Z, Peley G, et al. Relationship between sentinel lymph node status and regression of primary malignant melanoma. Melanoma Res. 2005;15(6):509-13.
32. Morris KT, Busam KJ, Bero S, Patel A, Brady MS. Primary cutaneous melanoma with regression does not require a lower threshold for sentinel lymph node biopsy. Ann Surg Oncol. 2008;15(1):316-22.
33. Mraz-Gernhard S, Sagebiel RW, Kashani-Sabet M, Miller JR, 3rd, Leong SP. Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanoma. Arch Dermatol. 1998;134(8):983-7.
34. Kroon HM, Lowe L, Wong S, et al. What is a sentinel node? Reevaluating the 10% rule for sentinel lymph node biopsy in melanoma. J Surg Oncol. 2007;95(8):623-8.
35. Nieweg OE, Estourgie SH. What is a sentinel node and what is a false-negative sentinel node? Ann Surg Oncol. 2004;11(3 Suppl): 169S-73S.
36. Bafounta ML, Beauchet A, Chagnon S, Saiag P. Ultrasonography or palpation for detection of melanoma nodal invasion: a metaanalysis. Lancet Oncol. 2004;5(11):673-80.
37. Rossi CR, Mocellin S, Scagnet B, et al. The role of preoperative ultrasound scan in detecting lymph node metastasis before sentinel node biopsy in melanoma patients. J Surg Oncol. 2003;83(2):80-4.
38. Starritt EC, Uren RF, Scolyer RA, Quinn MJ, Thompson JF. Ultrasound examination of sentinel nodes in the initial assessment of patients with primary cutaneous melanoma. Ann Surg Oncol. 2005;12(1):18-23.
39. Voit C, Kron M, Schafer G, et al. Ultrasound-guided fine needle aspiration cytology prior to sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol. 2006;13(12):1682-9.
40. Cook MG, Green MA, Anderson B, et al. The development of optimal pathological assessment of sentinel lymph nodes for melanoma. J Pathol. 2003;200(3):314-9.
41. Bedrosian I, Faries MB, Guerry D 4th, et al. Incidence of sentinel node metastasis in patients with thin primary melanoma (B1 mm) with vertical growth phase. Ann Surg Oncol. 2000;7(4):262-7.
42. Karakousis GC, Gimotty PA, Botbyl JD, et al. Predictors of regional nodal disease in patients with thin melanomas. Ann Surg Oncol. 2006;13(4):533-41.
43. Vaquerano J, Kraybill WG, Driscoll DL, Cheney R, Kane JM 3rd. American Joint Committee on Cancer clinical stage as a selection criterion for sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol. 2006;13(2):198-204.
44. Wong SL, Brady MS, Busam KJ, Coit DG. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol. 2006;13(3):302-9.
45. Yee VS, Thompson JF, McKinnon JG, et al. Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy. Ann Surg Oncol. 2005;12(6):429-39.
46. Roulin D, Matter M, Bady P, et al. Prognostic value of sentinel node biopsy in 327 prospective melanoma patients from a single institution. Eur J Surg Oncol. 2008;34(6):673-9.